Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.70 |
| ▸ | CSF1R | P07333 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | BRAF | P15056 | 2/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.62 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.62 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.62 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697489 | 0.90 | MAPT (0.68) | PTGS1CSF1RCYP2C9BRAFJAK2 | |
| SCHEMBL17103625 | 0.86 | PTGS1 (0.71) | PTGS1CSF1RMAPK14MAPTKCNK3 | |
| SCHEMBL14468045 | 0.85 | MEN1 (0.68) | PTGS1CSF1RCYP2C9BRAFMAPK14 | |
| SCHEMBL374471 | 0.85 | PTGS1 (0.70) | PTGS1CSF1RCYP2C9BRAFMAPK14 | |
| SCHEMBL31650037 | 0.84 | KDR (0.66) | PTGS1MAPTLMNAMEN1HTT | |
| SCHEMBL2497820 | 0.84 | CSF1R (0.70) | PTGS1CSF1RCYP2C9BRAFJAK2 | |
| Hydrochloric Acid SCHEMBL5004557 | 0.84 | PTGS1 (0.68) | PTGS1CSF1RCYP2C9BRAFMAPK14 | |
| SCHEMBL5504593 | 0.83 | MAPT (0.66) | PTGS1CSF1RCYP2C9BRAFJAK2 | |
| SCHEMBL2495506 | 0.82 | MAPT (0.61) | PTGS1CSF1RCYP2C9BRAFJAK2 | |
| SCHEMBL2495539 | 0.82 | MAPT (0.61) | PTGS1CSF1RCYP2C9BRAFJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| CN-101351467-A | 3- (substituted amino) -pyrazolo [3, 4-d ] pyrimidines as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2009-01-21 | — | — | CN | disclosed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | PTGS1 1316/4885CSF1R 818/4885CYP2C9 1246/4885 |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | PTGS1 2192/4885CSF1R 575/4885CYP2C9 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.